Hepatoprotective and anti-inflammatory profile of sokeikakketsuto and makyoyokukanto in primary cultured rat hepatocytes

Authors

  • Tatsuma Sakaguchi Kansai Medical University, Department of Surgery
  • Tetsuya Okuyama Kansai Medical University, Department of Surgery
  • Masaya Kotsuka Kansai Medical University, Department of Surgery
  • Terufumi Yoshida Kansai Medical University, Department of Surgery
  • Tadayoshi Okumura Kansai Medical University, Department of Surgery, Research Organization of Science and Technology, Ritsumeikan University
  • Mikio Nishizawa Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Japan
  • Masaki Kaibori Kansai Medical University, Department of Surgery
  • Mitsugu Sekimoto Kansai Medical University, Department of Surgery

DOI:

https://doi.org/10.31989/ffhd.v12i2.887

Abstract

Background: Sokeikakketsuto (SOK) is a Kampo medicine that can mitigate several types of pain, including arthralgia, neuralgia, low back pain, and myalgia, which may be introduced for the treatment of neuropathic pain in anti-cancer therapy. Considering that several Kampo medicines are known to have hepatoprotective and anti-inflammatory effects, we investigated the pharmacological mechanism of SOK in hepatocytes. Additionally, we examined another Kampo medicine, makyoyokukanto (MAK), as a reference as it has been reported to have similar efficacy for neuropathic pain.

Methods: SOK or MAK was incubated with rat primary cultured hepatocytes treated with interleukin (IL)-1β. The induction of inducible nitric oxide synthase (iNOS), nitric oxide (NO) production, iNOS signaling pathways, and the expression of other inflammatory mediators was investigated.

Results: IL-1β activated iNOS induction, followed by NO production. SOK and MAK reduced the expression of iNOS mRNA and its protein and decreased NO production. SOK and MAK also decreased the levels of tumor necrosis factor (TNF)-α and increased the levels of IL-6 and IL-1β. Transfection experiments with iNOS promoter-luciferase constructs revealed that MAK reduced iNOS mRNA synthesis and stability; however, SOK only reduced mRNA synthesis. Both medicines suppressed the activation of nuclear factor (NF)-κB but did not block the upregulation of type I IL-1 receptor in two essential signaling pathways.

Conclusions: SOK and MAK could prevent NO production by inhibiting iNOS gene expression, partly through NF-κB activation, in inflamed hepatocytes. However, both medicines may have different mechanisms of action in the treatment of injured organs.

Keywords: Kampo medicine, sokeikakketsuto, makyoyokukanto, inducible nitric oxide synthase, cultured hepatocytes

SOK and MAK reduced the expression of iNOS mRNA in inflamed hepatocytes.

Downloads

Published

2022-02-15

Issue

Vol. 12 No. 2 (2022): February 2022

Section

Research Articles

License

Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request. 

 

Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.